Dec '25 (edited) • General Discussion
Research Use Only Update & My Plan
Peptide + GLP-1 access update (no panic — just clarity 🤍)
What this means for you:
- Expect more noise online and more disruption for sellers
- RUO peptide sites, are facing the unknown. Some may shut down and some are updating language, names, removing certain peptides, etc.
- I have not heard anything specific from Biolongevity Labs or Limitless Biotech, BUT will keep you posted. In the meantime they have an epic sale going on at BLL through end of the year, and my suggestion is to stock up, just in case. Powder vials (not reconstituted) are good for 2 years in the freezer. **This is not to create fear, just convenience. 40% off Peptides, plus 15% off in addition with my code, Jess15 https://go.biolongevitylabs.com/aff_c?offer_id=1&aff_id=1488 (code: Jess15)
- My plan (important): Because enforcement is increasing around non-prescription online sales, I’m expanding access through a licensed provider + prescription model (Asher Med) using compliant compounding partners when appropriate. Launching next week. So clients can continue accessing GLP-1 options + a broader portfolio of peptides through a more compliant model. If you want to be first in line for the launch details, comment “CLARITY” or DM me “Asher” and I’ll send the steps + what to expect. Attaching peptides I will have available compliant, via prescription, shipped to 50 states. Will it be more expensive, yes - because its medically guided, but I will do my best to keep costs low.
----------------------------------------
Here’s what’s actually going on — in plain English:
- This isn’t one single “ban date.” What we’re seeing is a gradual tightening: more enforcement, more import screening, and more pressure on sellers who market “research use” products as if they’re for human use. Theres also pressure on Compound Pharmacies...
- FDA is specifically calling out “RUO” labeling used as a loophole.
FDA has warned research use companies selling unapproved GLP-1/GLP-1-like products that are labeled “for research” or “not for human consumption” when they’re clearly being sold to consumers for human use. Which, many of us use.
- Theres fresh legislation:
A new bill — the SAFE Drugs Act (H.R. 6509, introduced Dec 9, 2025) — aims to further regulate compounding/outsourcing facilities.
This is the newest headline-maker. It’s framed as a crackdown on mass-compounded copies of branded drugs (think GLP-1s) and tighter oversight of compounders. Why it matters to the peptide conversation: if access to compounded GLP-1s gets squeezed, some people assume that pushes more demand into “research-use” channels—then they leap to “RUO peptides are getting banned.” The bill itself is about compounding, not an RUO marketplace ban.
- Another bill — H.R. 5316 (introduced Sep 11, 2025) — focuses on access to certain compounded meds during shortages/urgent-use situations. This one is basically the opposite direction: it tries to clarify/expand when compounding is permitted during shortages/urgent-use situations (how far, how long, and under what conditions). https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss?utm_source=chatgpt.com
- In July, Import rules already got tighter this year, as of July 9, 2025, FDA began requiring screening for all imports of FDA-regulated products, even low-value shipments that previously moved with less oversight. https://www.whitehouse.gov/presidential-actions/2025/07/suspending-duty-free-de-minimis-treatment-for-all-countries/?utm_source=chatgpt.com
1
1 comment
Research Use Only Update & My Plan
powered by
skool.com/glp-1-peptide-clarity-group-5837
Learn how Peptides, GLP-1s, and lifestyle strategies support energy, balance, body composition, and lasting vitality from within.
Suggested communities
Powered by